Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that was previously used to treat rheumatism and other inflammatory conditions. It possesses anti-inflammatory, analgesic, and antipyretic properties. Fenclofenac acts primarily by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, leading to reduced synthesis of prostaglandins involved in pain, inflammation, and fever[2][3][4]. The drug also exhibits mild immunosuppressive effects and can displace thyroid hormones from their binding proteins, which may affect thyroid function[1][5][8]. Despite passing animal toxicity tests in multiple species, fenclofenac was found to cause severe liver toxicity in humans. Due to its side effects—including hepatotoxicity and potential for causing lichen planus—it was withdrawn from the market in the UK (1984) and US during the 1980s[1][2][7]. Indications included pain management (such as dysmenorrhea), ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, actinic keratosis, and general rheumatic diseases[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenclofenac.